Clinical Trials Directory

Trials / Sponsors / Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals, Inc.

Industry · 13 registered clinical trials.

StatusTrialPhaseStarted
Active Not RecruitingStudy of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINA
Solid Tumor
Phase 22019-10-29
TerminatedA Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Mel
Metastatic Melanoma
Phase 32018-05-30
CompletedA Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
Refractory Solid Tumors, Melanoma
Phase 12017-06-09
CompletedA Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic
Metastatic Melanoma
Phase 22015-12-01
CompletedTrial of IMO-8400 in Adult Patients With Dermatomyositis
Dermatomyositis
Phase 22015-11-01
CompletedExtension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401
Waldenstrom's Macroglobulinemia
Phase 1 / Phase 22014-11-01
CompletedDose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation
Diffuse Large B Cell Lymphoma
Phase 1 / Phase 22014-06-01
TerminatedPhase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemia
Phase 1 / Phase 22014-03-01
CompletedA 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Phase 22013-05-01
CompletedTrial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis
Actively Extending Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Phase 22012-05-01
CompletedStudy of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients
Hepatitis C, Treatment Naïve, Genotype 1 Patients
Phase 12009-09-01
CompletedPlacebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepa
Hepatitis C
Phase 12007-09-01
CompletedStudy of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
Renal Cell Carcinoma
Phase 22004-06-01